dechra pharmaceuticals limited
dechra pharmaceuticals limited Company Information
Company Number
03369634
Next Accounts
Mar 2026
Shareholders
dechra pharmaceuticals holdings limited
Group Structure
View All
Industry
Activities of head offices
Registered Address
24, cheshire avenue cheshire busines, northwich, CW9 7UA
Website
www.dechra.comdechra pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DECHRA PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 0.49x industry multiple (adjusted for size and gross margin).
dechra pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DECHRA PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-32.2m and a 3.89x industry multiple (adjusted for size and gross margin).
dechra pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DECHRA PHARMACEUTICALS LIMITED at £1.6b based on Net Assets of £771.4m and 2.11x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Dechra Pharmaceuticals Limited Overview
Dechra Pharmaceuticals Limited is a live company located in northwich, CW9 7UA with a Companies House number of 03369634. It operates in the activities of head offices sector, SIC Code 70100. Founded in May 1997, it's largest shareholder is dechra pharmaceuticals holdings limited with a 100% stake. Dechra Pharmaceuticals Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Dechra Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Dechra Pharmaceuticals Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 3 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Growth
3 year (CAGR) sales growth of -100%, show it is growing at a slower rate (9.7%)
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Employees
with 91 employees, this is below the industry average (114)
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Pay Structure
on an average salary of £86.5k, the company has a higher pay structure (£49.4k)
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 25 weeks, this is more cash available to meet short term requirements (16 weeks)
- - Dechra Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 48.3%, this is a lower level of debt than the average (54.4%)
- - Dechra Pharmaceuticals Limited
- - Industry AVG
DECHRA PHARMACEUTICALS LIMITED financials
Dechra Pharmaceuticals Limited's latest turnover from June 2024 is 0 and the company has net assets of £771.4 million. According to their latest financial statements, Dechra Pharmaceuticals Limited has 91 employees and maintains cash reserves of £104 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 761,500,000 | 681,800,000 | 608,000,000 | 515,100,000 | 481,800,000 | 407,100,000 | 359,300,000 | 247,562,000 | 203,480,000 | 193,571,000 | 189,176,000 | 124,330,000 | 389,237,000 | 369,369,000 | |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 335,200,000 | 297,000,000 | 262,100,000 | 223,500,000 | 208,700,000 | 184,700,000 | 167,600,000 | 115,122,000 | 87,338,000 | 85,863,000 | 88,470,000 | 53,220,000 | 300,876,000 | 288,744,000 | |
| Gross Profit | 426,300,000 | 384,800,000 | 345,900,000 | 291,600,000 | 273,100,000 | 222,400,000 | 191,700,000 | 132,440,000 | 116,142,000 | 107,708,000 | 100,706,000 | 71,110,000 | 88,361,000 | 80,625,000 | |
| Admin Expenses | 420,000,000 | 289,300,000 | 261,900,000 | 239,400,000 | 234,100,000 | 188,300,000 | 158,500,000 | 112,947,000 | 90,162,000 | 82,712,000 | 82,370,000 | 60,838,000 | 66,643,000 | 100,491,000 | |
| Operating Profit | -34,871,000 | 6,300,000 | 95,500,000 | 84,000,000 | 52,200,000 | 39,000,000 | 34,100,000 | 33,200,000 | 19,493,000 | 25,980,000 | 24,996,000 | 18,336,000 | 10,272,000 | 21,718,000 | -19,866,000 |
| Interest Payable | 60,007,000 | 46,000,000 | 22,300,000 | 12,700,000 | 14,000,000 | 11,500,000 | 6,400,000 | 5,300,000 | 2,389,000 | 1,416,000 | 3,658,000 | 5,448,000 | 3,320,000 | 5,348,000 | 3,766,000 |
| Interest Receivable | 22,967,000 | 4,500,000 | 5,700,000 | 3,800,000 | 3,000,000 | 200,000 | 200,000 | 21,000 | 26,000 | 302,000 | 73,000 | 80,000 | 1,145,000 | 1,006,000 | |
| Pre-Tax Profit | -80,507,000 | -36,100,000 | 77,600,000 | 74,000,000 | 40,900,000 | 27,800,000 | 28,900,000 | 28,600,000 | 14,548,000 | 25,806,000 | 21,442,000 | 12,478,000 | 6,112,000 | 18,514,000 | 17,732,000 |
| Tax | 1,692,000 | 8,200,000 | -19,400,000 | -18,500,000 | -7,000,000 | 3,100,000 | 7,200,000 | -2,500,000 | -2,036,000 | -6,347,000 | -2,026,000 | -1,628,000 | -2,207,000 | -4,380,000 | -4,575,000 |
| Profit After Tax | -78,815,000 | -27,900,000 | 58,200,000 | 55,500,000 | 33,900,000 | 30,900,000 | 36,100,000 | 26,100,000 | 12,512,000 | 19,459,000 | 19,416,000 | 10,850,000 | 3,905,000 | 14,134,000 | 13,157,000 |
| Dividends Paid | 44,800,000 | 37,900,000 | 33,300,000 | 28,400,000 | 21,800,000 | 17,700,000 | 15,292,000 | 13,857,000 | 12,579,000 | 11,170,000 | 8,325,000 | 7,221,000 | 6,195,000 | ||
| Retained Profit | -78,815,000 | -27,900,000 | 13,400,000 | 17,600,000 | 600,000 | 2,500,000 | 14,300,000 | 8,400,000 | -2,624,000 | 5,602,000 | 6,837,000 | 6,743,000 | 3,424,000 | 6,913,000 | 6,962,000 |
| Employee Costs | 7,875,000 | 163,800,000 | 131,600,000 | 120,300,000 | 104,000,000 | 92,700,000 | 88,200,000 | 76,100,000 | 56,504,000 | 45,613,000 | 41,624,000 | 50,952,000 | 37,014,000 | 33,248,000 | 31,179,000 |
| Number Of Employees | 91 | 2,335 | 2,036 | 1,945 | 1,850 | 1,731 | 1,437 | 1,338 | 1,308 | 863 | 763 | 1,287 | 1,042 | 1,005 | 1,021 |
| EBITDA* | -32,180,000 | 96,000,000 | 183,900,000 | 174,500,000 | 136,000,000 | 127,700,000 | 95,500,000 | 80,500,000 | 44,808,000 | 47,518,000 | 45,521,000 | 41,007,000 | 24,618,000 | 33,589,000 | -10,449,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,691,000 | 184,000,000 | 122,200,000 | 110,200,000 | 101,900,000 | 69,400,000 | 59,600,000 | 56,800,000 | 38,526,000 | 18,219,000 | 18,258,000 | 16,074,000 | 18,677,000 | 7,721,000 | 7,673,000 |
| Intangible Assets | 1,961,000 | 922,400,000 | 730,500,000 | 715,800,000 | 692,200,000 | 680,600,000 | 709,800,000 | 396,300,000 | 355,258,000 | 166,684,000 | 196,182,000 | 219,596,000 | 225,872,000 | 125,098,000 | 80,371,000 |
| Investments & Other | 920,159,000 | 14,900,000 | 17,300,000 | 19,200,000 | 20,100,000 | 10,100,000 | 10,500,000 | 10,800,000 | 342,000 | 1,957,000 | |||||
| Debtors (Due After 1 year) | 4,900,000 | 2,300,000 | 2,000,000 | 2,700,000 | |||||||||||
| Total Fixed Assets | 923,811,000 | 1,101,500,000 | 850,400,000 | 824,000,000 | 791,400,000 | 750,000,000 | 769,400,000 | 453,100,000 | 393,784,000 | 184,903,000 | 214,440,000 | 235,670,000 | 244,549,000 | 132,819,000 | 88,044,000 |
| Stock & work in progress | 217,300,000 | 175,700,000 | 149,500,000 | 120,800,000 | 103,500,000 | 86,600,000 | 56,500,000 | 54,375,000 | 31,744,000 | 29,673,000 | 29,199,000 | 57,281,000 | 40,760,000 | 34,819,000 | |
| Trade Debtors | 144,200,000 | 122,100,000 | 88,200,000 | 79,400,000 | 91,100,000 | 76,000,000 | 59,700,000 | 59,232,000 | 27,705,000 | 28,325,000 | 25,296,000 | 69,596,000 | 62,212,000 | 48,293,000 | |
| Group Debtors | 460,923,000 | ||||||||||||||
| Misc Debtors | 3,686,000 | 17,700,000 | 14,700,000 | 18,500,000 | 14,500,000 | 8,700,000 | 5,600,000 | 7,600,000 | 9,637,000 | 3,227,000 | 1,563,000 | 2,386,000 | 2,517,000 | 4,081,000 | 2,869,000 |
| Cash | 104,011,000 | 74,400,000 | 120,900,000 | 118,400,000 | 227,400,000 | 80,300,000 | 79,700,000 | 61,200,000 | 39,142,000 | 45,948,000 | 26,773,000 | 32,791,000 | 32,435,000 | 30,496,000 | 31,502,000 |
| misc current assets | 10,600,000 | 89,784,000 | 589,000 | ||||||||||||
| total current assets | 568,620,000 | 467,900,000 | 444,400,000 | 392,200,000 | 448,900,000 | 294,200,000 | 247,900,000 | 185,000,000 | 162,386,000 | 108,624,000 | 86,334,000 | 179,456,000 | 162,418,000 | 137,549,000 | 117,483,000 |
| total assets | 1,492,431,000 | 1,569,400,000 | 1,294,800,000 | 1,216,200,000 | 1,240,300,000 | 1,044,200,000 | 1,017,300,000 | 638,100,000 | 556,170,000 | 293,527,000 | 300,774,000 | 415,126,000 | 406,967,000 | 270,368,000 | 205,527,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | 1,400,000 | 1,200,000 | 1,200,000 | 1,000,000 | 1,648,000 | 9,412,000 | 5,000,000 | 8,000,000 | 20,000,000 | ||||||
| Trade Creditors | 1,334,000 | 43,400,000 | 46,000,000 | 35,200,000 | 34,600,000 | 31,900,000 | 33,000,000 | 21,400,000 | 24,326,000 | 10,370,000 | 12,867,000 | 11,859,000 | 63,559,000 | 63,213,000 | 56,465,000 |
| Group/Directors Accounts | 212,611,000 | ||||||||||||||
| other short term finances | 301,000 | 4,100,000 | 6,400,000 | 22,600,000 | 8,800,000 | 1,600,000 | 517,000 | 138,000 | 957,000 | 573,000 | |||||
| hp & lease commitments | 3,900,000 | 3,300,000 | 3,100,000 | 3,200,000 | 24,000 | 8,000 | 103,000 | 338,000 | 695,000 | 502,000 | 441,000 | ||||
| other current liabilities | 1,939,000 | 112,600,000 | 103,000,000 | 94,900,000 | 98,100,000 | 85,000,000 | 48,600,000 | 42,400,000 | 39,467,000 | 33,593,000 | 22,745,000 | 80,953,000 | 34,796,000 | 17,237,000 | 11,562,000 |
| total current liabilities | 216,185,000 | 164,000,000 | 158,700,000 | 155,800,000 | 137,300,000 | 118,100,000 | 91,600,000 | 66,400,000 | 65,982,000 | 44,109,000 | 35,715,000 | 103,519,000 | 104,050,000 | 88,952,000 | 89,041,000 |
| loans | 504,856,000 | 1,144,400,000 | 654,600,000 | 635,200,000 | 706,200,000 | 619,200,000 | 635,800,000 | 427,200,000 | 312,036,000 | 65,038,000 | 63,320,000 | 212,651,000 | 232,006,000 | 112,170,000 | 35,524,000 |
| hp & lease commitments | 500,600,000 | 12,100,000 | 12,800,000 | 11,800,000 | 7,000 | 142,000 | 246,000 | 339,000 | 729,000 | ||||||
| Accruals and Deferred Income | 200,000 | 3,412,000 | 6,025,000 | 3,526,000 | |||||||||||
| other liabilities | 104,000,000 | 57,600,000 | 47,300,000 | 30,900,000 | 1,311,000 | 1,070,000 | 13,555,000 | ||||||||
| provisions | 156,000,000 | 76,000,000 | 104,600,000 | 130,200,000 | 153,000,000 | 205,200,000 | 111,000,000 | 111,950,000 | 35,376,000 | 42,996,000 | 56,360,000 | 59,412,000 | 26,886,000 | 24,992,000 | |
| total long term liabilities | 504,856,000 | 650,200,000 | 469,300,000 | 427,500,000 | 465,500,000 | 417,000,000 | 420,700,000 | 269,100,000 | 213,576,000 | 54,930,000 | 60,253,000 | 136,991,000 | 149,235,000 | 83,083,000 | 30,258,000 |
| total liabilities | 721,041,000 | 814,200,000 | 628,000,000 | 583,300,000 | 602,800,000 | 535,100,000 | 512,300,000 | 335,500,000 | 279,558,000 | 99,039,000 | 95,968,000 | 240,510,000 | 253,285,000 | 172,035,000 | 119,299,000 |
| net assets | 771,390,000 | 755,200,000 | 666,800,000 | 632,900,000 | 637,500,000 | 509,100,000 | 505,000,000 | 301,000,000 | 274,631,000 | 194,488,000 | 204,806,000 | 174,616,000 | 153,682,000 | 98,333,000 | 86,228,000 |
| total shareholders funds | 771,390,000 | 755,200,000 | 666,800,000 | 632,900,000 | 637,500,000 | 509,100,000 | 505,000,000 | 301,000,000 | 274,631,000 | 194,488,000 | 204,806,000 | 174,616,000 | 153,682,000 | 98,333,000 | 86,228,000 |
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -34,871,000 | 6,300,000 | 95,500,000 | 84,000,000 | 52,200,000 | 39,000,000 | 34,100,000 | 33,200,000 | 19,493,000 | 25,980,000 | 24,996,000 | 18,336,000 | 10,272,000 | 21,718,000 | -19,866,000 |
| Depreciation | 372,000 | 13,700,000 | 11,100,000 | 11,000,000 | 9,900,000 | 7,800,000 | 4,800,000 | 4,900,000 | 3,763,000 | 2,412,000 | 2,185,000 | 2,795,000 | 1,584,000 | 1,509,000 | 1,509,000 |
| Amortisation | 2,319,000 | 76,000,000 | 77,300,000 | 79,500,000 | 73,900,000 | 80,900,000 | 56,600,000 | 42,400,000 | 21,552,000 | 19,126,000 | 18,340,000 | 19,876,000 | 12,762,000 | 10,362,000 | 7,908,000 |
| Tax | 1,692,000 | 8,200,000 | -19,400,000 | -18,500,000 | -7,000,000 | 3,100,000 | 7,200,000 | -2,500,000 | -2,036,000 | -6,347,000 | -2,026,000 | -1,628,000 | -2,207,000 | -4,380,000 | -4,575,000 |
| Stock | -217,300,000 | 41,600,000 | 26,200,000 | 28,700,000 | 17,300,000 | 16,900,000 | 30,100,000 | 2,125,000 | 22,631,000 | 2,071,000 | 474,000 | -28,082,000 | 16,521,000 | 5,941,000 | 34,819,000 |
| Debtors | 297,809,000 | 27,700,000 | 30,400,000 | 12,100,000 | -3,200,000 | 18,200,000 | 14,300,000 | -1,569,000 | 37,937,000 | 1,044,000 | 2,206,000 | -44,431,000 | 5,820,000 | 15,131,000 | 51,162,000 |
| Creditors | -42,066,000 | -2,600,000 | 10,800,000 | 600,000 | 2,700,000 | -1,100,000 | 11,600,000 | -2,926,000 | 13,956,000 | -2,497,000 | 1,008,000 | -51,700,000 | 346,000 | 6,748,000 | 56,465,000 |
| Accruals and Deferred Income | -110,661,000 | 9,600,000 | 8,100,000 | -3,200,000 | 13,100,000 | 36,200,000 | 6,400,000 | 2,933,000 | 2,462,000 | 8,235,000 | -52,183,000 | 42,631,000 | 21,085,000 | 5,675,000 | 11,562,000 |
| Deferred Taxes & Provisions | -156,000,000 | 80,000,000 | -28,600,000 | -25,600,000 | -22,800,000 | -52,200,000 | 94,200,000 | -950,000 | 76,574,000 | -7,620,000 | -13,364,000 | -3,052,000 | 32,526,000 | 1,894,000 | 24,992,000 |
| Cash flow from operations | -419,724,000 | 121,900,000 | 98,200,000 | 87,000,000 | 107,900,000 | 78,600,000 | 170,500,000 | 76,501,000 | 75,196,000 | 36,174,000 | -23,724,000 | 99,771,000 | 54,027,000 | 22,454,000 | -7,986,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 905,259,000 | -2,400,000 | -1,900,000 | -900,000 | 10,000,000 | -400,000 | -300,000 | 10,458,000 | 342,000 | -1,957,000 | 1,957,000 | ||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | -1,400,000 | 200,000 | 200,000 | -648,000 | 1,648,000 | -9,412,000 | 4,412,000 | -3,000,000 | -12,000,000 | 20,000,000 | |||||
| Group/Directors Accounts | 212,611,000 | ||||||||||||||
| Other Short Term Loans | -3,799,000 | -2,300,000 | -16,200,000 | 22,600,000 | -8,800,000 | 7,200,000 | 1,083,000 | 379,000 | 138,000 | -957,000 | 957,000 | -573,000 | 573,000 | ||
| Long term loans | -639,544,000 | 489,800,000 | 19,400,000 | -71,000,000 | 87,000,000 | -16,600,000 | 208,600,000 | 115,164,000 | 246,998,000 | 1,718,000 | -149,331,000 | -19,355,000 | 119,836,000 | 76,646,000 | 35,524,000 |
| Hire Purchase and Lease Commitments | -504,500,000 | 489,100,000 | -500,000 | 900,000 | 15,000,000 | -24,000 | 16,000 | -102,000 | -370,000 | -461,000 | 100,000 | -329,000 | 1,170,000 | ||
| other long term liabilities | -104,000,000 | 46,400,000 | 10,300,000 | 16,400,000 | 30,900,000 | -1,311,000 | 241,000 | 1,070,000 | -13,555,000 | 13,555,000 | |||||
| share issue | |||||||||||||||
| interest | -37,040,000 | -41,500,000 | -16,600,000 | -8,900,000 | -11,000,000 | -11,500,000 | -6,200,000 | -5,100,000 | -2,368,000 | -1,390,000 | -3,356,000 | -5,375,000 | -3,240,000 | -4,203,000 | -2,760,000 |
| cash flow from financing | -877,267,000 | 947,400,000 | 53,000,000 | -69,700,000 | 235,400,000 | -4,400,000 | 399,500,000 | 128,444,000 | 328,129,000 | -15,315,000 | -139,003,000 | -5,631,000 | 152,066,000 | 78,288,000 | 133,773,000 |
| cash and cash equivalents | |||||||||||||||
| cash | 29,611,000 | -46,500,000 | 2,500,000 | -109,000,000 | 147,100,000 | 600,000 | 18,500,000 | 22,058,000 | -6,806,000 | 19,175,000 | -6,018,000 | 356,000 | 1,939,000 | -1,006,000 | 31,502,000 |
| overdraft | |||||||||||||||
| change in cash | 29,611,000 | -46,500,000 | 2,500,000 | -109,000,000 | 147,100,000 | 600,000 | 18,500,000 | 22,058,000 | -6,806,000 | 19,175,000 | -6,018,000 | 356,000 | 1,939,000 | -1,006,000 | 31,502,000 |
dechra pharmaceuticals limited Credit Report and Business Information
Dechra Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for dechra pharmaceuticals limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in CW9 area or any other competitors across 12 key performance metrics.
dechra pharmaceuticals limited Ownership
DECHRA PHARMACEUTICALS LIMITED group structure
Dechra Pharmaceuticals Limited has 4 subsidiary companies.
Ultimate parent company
FREYA POOLCO SARL
#0168355
2 parents
DECHRA PHARMACEUTICALS LIMITED
03369634
4 subsidiaries
dechra pharmaceuticals limited directors
Dechra Pharmaceuticals Limited currently has 4 directors. The longest serving directors include Mr Paul Sandland (Oct 2019) and Mr Jonathan Lang (Jun 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Paul Sandland | England | 46 years | Oct 2019 | - | Director |
| Mr Jonathan Lang | 51 years | Jun 2024 | - | Director | |
| Mr Jesper Nordengaard | United Kingdom | 49 years | Jun 2024 | - | Director |
| Mr Ajay Gandhi | 53 years | Mar 2025 | - | Director |
P&L
June 2024turnover
0
-100%
operating profit
-34.9m
-654%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
771.4m
+0.02%
total assets
1.5b
-0.05%
cash
104m
+0.4%
net assets
Total assets minus all liabilities
dechra pharmaceuticals limited company details
company number
03369634
Type
Private limited with Share Capital
industry
70100 - Activities of head offices
incorporation date
May 1997
age
28
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
June 2024
previous names
dechra pharmaceuticals plc (January 2024)
dechra pharmaceuticals limited (August 2000)
See moreaccountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
24, cheshire avenue cheshire busines, northwich, CW9 7UA
Bank
HSBC BANK PLC
Legal Advisor
-
dechra pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 14 charges/mortgages relating to dechra pharmaceuticals limited. Currently there are 1 open charges and 13 have been satisfied in the past.
dechra pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for DECHRA PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
dechra pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
